Photo Release -- Amarin Reports First Quarter 2013 Financial Results and Provides Update on Operations

Photo Release -- Amarin Reports First Quarter 2013 Financial Results and
Provides Update on Operations

Conference Call Set for 4:30 p.m. EDT Today

BEDMINSTER, N.J., and DUBLIN, Ireland, May 9, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused
on the commercialization and development of therapeutics to improve
cardiovascular health,today announced financial results for the quarter ended
March 31, 2013 and provided an update on company operations.

Vascepa 2013 TRx

Key Amarin accomplishments since the quarter ended December 31, 2012 include:

  *Launched Vascepa^® (icosapent ethyl) capsules in the United States on
    January 28, 2013 for the MARINE indication (use as an adjunct to diet to
    reduce triglyceride levels in adult patients with severe (≥500 mg/dL)
    hypertriglyceridemia)
  *Recognized $2.34 million in product revenue from Vascepa sales in Q1 in
    accordance with GAAP ($5.2 million in net value of Vascepa was sold to
    wholesalers in Q1, resulting in $2.9 million of deferred product revenue
    under GAAP in Q1)
  *Secured formulary access for Vascepa with over 190 million lives now
    covered by payors without restrictions, including 40 million converted to
    Tier 2 in April and May
  *Received Food and Drug Administration (FDA) acceptance for review of
    supplemental New Drug Application (sNDA) seeking approval for the
    marketing and sale of Vascepa for the ANCHOR indication (use as an adjunct
    to diet in the treatment of adult patients with high triglycerides (TG
    ≥200 mg/dL and <500 mg/dL) with mixed dyslipidemia)
  *Reported statistically significant reductions of apolipoprotein C-III (Apo
    C-III) of 25.1% and 19.2%, compared to placebo, as demonstrated by Vascepa
    in post-hoc analyses of the MARINE and ANCHOR Phase 3 clinical trials,
    respectively
  *Received FDA approval of two additional active pharmaceutical ingredient
    (API) suppliers, BASF and Chemport, for the manufacture of Vascepa giving
    Amarin three qualified API suppliers
  *Increased patents issued or allowed in the United States to 22 (adding 11
    in the first quarter alone, including 3 since our last patent
    announcement), all but two of which have patent terms extending into 2030,
    with more than 30 additional patent applications being prosecuted in the
    United States alone

"On January 28, 2013 Amarin launched Vascepa for use in its initial indication
as an adjunct to diet to reduce triglyceride levels in adult patients with
severe (≥500 mg/dL) hypertriglyceridemia, the MARINE indication," saidJoseph
Zakrzewski, Chairman and Chief Executive Officer of Amarin. "Since that day,
we have seen meaningful progress in multiple areas of our commercialization
strategy, including uptake in Vascepa utilization by physicians in both the
specialty and primary care communities, the initial migration of managed care
lives from Tier 3 to Tier 2 coverage, the continued expansion of our patent
portfolio, the further strengthening of our supply chain, and the acceptance
for review by the FDA of our sNDA for the ANCHOR indication, which, if
approved, would enable promotion of Vascepa to a significantly larger patient
population."

Operational update

Commercialization update

Amarin's direct sales force, consisting of approximately 275 sales
professionals, made sales calls to clinicians for two months in Q1 2013.
Amarin reports that, since launch, access to clinicians has been good, and
that it has yet to hear any significant negative reaction to the efficacy or
safety profile of Vascepa. Amarin's sales professionals are currently
targeting the limited group of clinicians who are the highest prescribers of
other lipid therapies. Vascepa is being marketed for use as an adjunct to diet
to reduce triglyceride levels in adult patients with severe (≥500 mg/dL)
hypertriglyceridemia, the initial indication for Vascepa. Amarin believes that
Vascepa is well differentiated in this market based on its safety profile,
which is similar to placebo, and its spectrum of demonstrated lipid benefit at
4g/day, including statistically significant reductions in triglycerides, Apo
B, VLDL-C, and non-HDL-C, with no increase in LDL-C, also known as bad
cholesterol.

A chart accompanying this press release is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=18620

Since launching Vascepa, Amarin has:

  *Witnessed steady increases in the number of clinicians prescribing Vascepa
    (now over 4,000), in the number of prescriptions reported (via third-party
    sources), in the number of bottles of Vascepa shipped from wholesalers to
    retail pharmacies and in the number of co-pay cards used by patients
  *Witnessed monthly volume (via third-party sources, often underestimated)
    increase with consistency in the first months post launch with
    prescriptions increasing from 3,224 to 7,260 to 11,768 normalized TRx,
    reported in February, March, and April, respectively (normalized TRx
    equates to 120 capsules, or one month's supply)
  *Focused on clinician education about Vascepa's clinical results and
    increased product awareness
  *Secured early managed care coverage based on the safety and efficacy
    profile of Vascepa, including initial Tier 2 conversions (without
    restrictions) in April and May, noting that it typically takes
    two-to-three months of time to translate into script data
  *Trained clinicians as speakers on behalf of Vascepa and conducted speaker
    programs for groups of healthcare professionals
  *Mitigated the Tier 3 vs. Tier 2 co-payment differential for patients with
    an actively used co-pay discount program (a common program for a new drug
    until Tier 2 coverage is secured)
  *Received early, but encouraging, feedback from clinicians regarding their
    patients' initial experiences with Vascepa

Vascepa additional indication progress

In parallel with marketing Vascepa for the MARINE indication, Amarin is
pursuing approval of Vascepa for the considerably larger ANCHOR indication. In
a clinical trial of the use of Vascepa in the ANCHOR indication, as previously
announced, Vascepa demonstrated statistically significant reductions in a
broad spectrum of lipid and inflammatory markers, on top of optimized statin
therapy, including significant reduction in LDL-C. In April 2013, as
previously announced, the FDA accepted for review Amarin's sNDA for the ANCHOR
indication that, upon approval, would enable Amarin to market and sell Vascepa
for use in the ANCHOR indication. The FDA assigned a PDUFA action date of
December 20, 2013 for this sNDA, which date is consistent with the standard
FDA ten-month review period. The safety results from the ANCHOR trial are
included in the current label for Vascepa. At a daily Vascepa dose of 4 grams,
all of the primary and secondary efficacy endpoints of the ANCHOR trial were
achieved. As a result, Amarin is optimistic that the FDA will approve Vascepa
for this indication.

Vascepa supply update

In the fourth quarter of 2012, Amarin submitted two sNDAs, one each for two
additional active pharmaceutical ingredient (API) suppliers for Vascepa: BASF
and Chemport. Both of these sNDA filings were approved in April 2013.
Qualification of these suppliers is part of Amarin's strategy to expand its
supply chain to provide greater capacity to meet anticipated demand, enable
supply diversification and flexibility and introduce cost competition among
high quality suppliers. With the approval of these suppliers, Amarin now has
three qualified API suppliers for Vascepa, enabling Amarin to potentially
reduce supply costs by 50% or more.

Vascepa exclusivity update

Amarin continues to make significant progress in its effort to expand patent
protection for Vascepa and now has 22 patents issued or allowed in the United
States with over 30 additional U.S. patent applications being prosecuted. This
patent portfolio includes claims covering Vascepa's pharmaceutical composition
and methods of use for the MARINE indication, ANCHOR indication and other
potential uses of Vascepa. Amarinis also pursuing patent applications related
to Vascepa in multiple jurisdictions outsidethe United States. All but two of
the granted patents have expiry dates extending into 2030 and the majority of
patent applications, if and when allowed, are anticipated to have expiry dates
in or beyond 2030. Patent protection for Vascepa is augmented by protection
provided by trade secrets, manufacturing barriers to entry and three- or
five-year regulatory exclusivity.

REDUCE-IT and other Vascepa-related clinical development

Amarin continues to progress patient enrollment in its REDUCE-IT
cardiovascular outcomes study with more than 4,000 patients enrolled in the
study to date. Amarin anticipates continuing to enroll patients in this study
throughout 2013. Results of the study will not be available until a specified
number of cardiovascular events have been observed, the timing of which is not
expected in the near-term.

Financial update

Amarin reported cash and cash equivalents of $201.8 million at March 31, 2013.

Amarin reported net product revenues for the quarter ended March 31, 2013 of
$2.34 million under U.S. Generally Accepted Accounting Principles (GAAP). In
accordance with GAAP, until Amarin has more experience in the
commercialization of Vascepa, Amarin plans to recognize revenue based on the
resale of Vascepa by the wholesalers to which Amarin sells Vascepa, and not
based on sales from Amarin to such wholesalers. During the quarter ended March
31, 2013, the net value of Vascepa sold to wholesalers was $5.2 million,
which, in accordance with GAAP, resulted in $2.9 million of deferred product
revenue from Vascepa sales in the quarter ended March 31, 2013.

Consistent with industry practice, the net price of Vascepa in the quarter
ended March 31, 2013 reflects the deduction of one-time discounts paid to
wholesalers to stock Vascepa in advance of the launch of Vascepa on January
28, 2013 as well as the costs of Amarin's 2013 co-payment rebate card program
and customary payor rebates and allowances.

Cost of goods sold during the quarter ended March 31, 2013 was $1.3 million.
All of the API sold during the first quarter of 2013 was sourced from a single
API supplier. As previously commented, Amarin's purchases of API from that
supplier in 2012 and Q1 2013 are at a higher cost/kg than scheduled future
purchases from such supplier. The unusually high cost of goods percentage is
attributable to start up costs, geography, special launch related discounts to
wholesalers, exchange rate exposure, lower volume, our co-payment rebate card
program and less favorable terms than exist with other suppliers. Amarin
expects steady state gross margins to approach the high seventies to eighty
percent level. In future periods, Amarin also anticipates purchasing API from
BASF and Chemport, the sNDAs for which were approved in April 2013. The API
cost/kg from BASF and Chemport are also significantly lower than the costs
incurred for past purchases of API from our single initial supplier.

Under GAAP, Amarin reported a net loss of $62.2 million in the first quarter
of 2013, or basic and diluted loss per share of $0.41. This net loss included
$4.9 million in non-cash share-based compensation expense, $0.5 million in
non-cash warrant compensation income, and a $3.6 million gain on the change in
the fair value of derivatives. In the first quarter of 2012, GAAP net loss was
$88.3 million, or basic and diluted loss per share of $0.65, and included $3.9
million in non-cash share-based compensation expense, $2.4 million in non-cash
warrant compensation expense, and a $66.2 million loss on the change in the
fair value of derivatives.

Excluding non-cash gains or losses for share-based compensation, warrant
compensation and change in value of derivatives, non-GAAP adjusted net loss
was $61.4 million for the first quarter of 2013, or non-GAAP adjusted basic
and diluted loss per share of $0.41, compared to non-GAAP adjusted net loss of
$15.8 million, or non-GAAP adjusted basic and diluted loss per share of $0.12
for the same period in 2012.

During the three months endedMarch 31, 2013, net cash decreased by
approximately$58.4 million, including approximately $32.0 million paid for
sales and marketing related expenses in connection with the initial commercial
launch of Vascepa, approximately $13.0 million paid in support of the
REDUCE-IT cardiovascular outcomes study and approximately $11.8 million for
Vascepa API purchased in connection with the buildup of our commercial supply
and for clinical trial material. During the three months ended March 31, 2013,
research and development expense included $3.0 million for API from suppliers
which were not approved until April 2013 which, for accounting purposes, was
expensed in the period received.

As of March 31, 2013, Amarin had approximately 150.7 million ADSs outstanding
as well as approximately 9.9 million, 11.3 million, and 0.9 million equivalent
shares underlying warrants, stock options, and restricted or deferred stock
units, respectively, at average exercise prices of $1.44, $7.45 and $8.49,
respectively. In addition, our $150 million exchangeable senior notes issued
in January 2012 are exchangeable prior toOctober 15, 2031 into an aggregate
of 17.0 million ADSs (based on an initial exchange price of
approximately$8.81per ADS), subject to certain specified conditions. The
notes accrue interest at an annual rate of 3.5%, payable semiannually in
arrears on January 15 and July 15, beginning July 15, 2012. The notes will
mature on January 15, 2032, unless earlier repurchased or redeemed by the
company or exchanged by the holders.

Amarin's 2013 operational priorities

Operational priorities in 2013 are:

  *Increasing revenues from sales of Vascepa
  *Continuing managed care migration from Tier 3 to Tier 2 coverage
  *Gaining approval of the ANCHOR indication sNDA (PDUFA date of December 20,
    2013)
  *Planning for the commercialization of the ANCHOR indication
  *Obtaining additional patent awards from the USPTO
  *Continuing development of a fixed-dose combination of Vascepa and a
    leading statin
  *Submitting an sNDA for a fourth API supplier
  *Publishing additional data from Amarin's clinical trials
  *Obtaining FDA exclusivity determination

Conference call and webcast information

Amarinwill host a conference call at4:30 p.m. EDT(8:30 p.m. UTC/GMT)
today,May 9, 2013. To participate in the call, please dial (877) 407-8033
within the United States or (201) 689-8033 from outside the United States. A
replay of the call will be made available for a period of two weeks following
the conference call. To hear a replay of the call, dial (877) 660-6853 (inside
the U.S.) or (201) 612-7415 (outside the U.S.). A replay of the call will also
be available through Amarin's website shortly after the call. For both dial-in
numbers please use conference ID 411140. The conference call can also be heard
live through the investor relations section of Amarin's website
atwww.amarincorp.com.

Use of non-GAAP adjusted financial information

Included in this press release and the conference call referenced above are
non-GAAP adjusted financial information as defined by U.S. Securities and
Exchange Commission Regulation G. The GAAP financial measure most directly
comparable to each non-GAAP adjusted financial measure used or discussed, and
a reconciliation of the differences between each non-GAAP adjusted financial
measure and the comparable GAAP financial measure, are included in this press
release after the condensed consolidated financial statements.

Non-GAAP adjusted net loss was derived by taking GAAP net loss and adjusting
it with non-cash gains or losses for share-based compensation, warrant
compensation, and change in value of derivative. Management believes that
these non-GAAP adjusted measures provide investors with a better understanding
of the company's historical results from its core business operations.

While management believes that these non-GAAP adjusted financial measures
provide useful supplemental information to investors regarding the underlying
performance of the company's business operations, investors are reminded to
consider these non-GAAP measures in addition to, and not as a substitute for,
financial performance measures prepared in accordance with GAAP. Non-GAAP
measures have limitations in that they do not reflect all of the amounts
associated with the company's results of operations as determined in
accordance with GAAP. In addition, it should be noted that these non-GAAP
financial measures may be different from non-GAAP measures used by other
companies, and management may utilize other measures to illustrate performance
in the future.

About Vascepa®(icosapent ethyl) capsules

Vascepa®(icosapent ethyl) capsules, known in scientific literature as AMR101,
is a highly pure-EPAomega-3 prescription product in a 1 gram capsule.

Indications and Usage

  *Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce
    triglyceride (TG) levels in adult patients with severe (≥500 mg/dL)
    hypertriglyceridemia.
  *The effect of Vascepa on the risk for pancreatitis and cardiovascular
    mortality and morbidity in patients with severe hypertriglyceridemia has
    not been determined.

Important Safety Information for Vascepa

  *Vascepa is contraindicated in patients with known hypersensitivity (e.g.,
    anaphylactic reaction) to Vascepa or any of its components and should be
    used with caution in patients with known hypersensitivity to fish and/or
    shellfish.
  *The most common reported adverse reaction (incidence >2% and greater than
    placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo).

FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND ATWWW.VASCEPA.COM.

Forward-looking statements

This press release contains forward-looking statements, including statements
about the commercial launch of Vascepa, including the number of total
prescriptions to date and sales trends, expectations for revenue growth,
product awareness, receptivity of clinicians to and patient experience with
Vascepa; expectations regarding managed care migration from Tier 3 to Tier 2
coverage and continued growth in Tier 2 coverage; the pricing terms of
commercial supply for Vascepa; expectations regarding gross margins and cost
of goods sold (COGS); the timing of FDA decisions regarding Amarin's sNDA for
the ANCHOR indication and regulatory exclusivity; the efficacy, safety and
therapeutic benefits of Vascepa; the ability of Amarin to develop a fixed-dose
combination of Vascepa and a leading statin; Amarin's ability to obtain
sufficient patent protection and regulatory exclusivity for its product and
product candidates, maintain trade secrets, and take advantage of
manufacturing barriers to entry; continued enrollment of patients in Amarin's
REDUCE-IT cardiovascular outcomes study; continued publication of study data;
and continued assessment of collaboration prospects for commercialization of
Vascepa. These forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. In particular, as disclosed in
its previous filings with the U.S. Securities and Exchange Commission,
Amarin's ability to effectively commercialize Vascepa will depend in part on
its ability to create market demand for Vascepa through education, marketing
and sales activities, to achieve market acceptance of Vascepa, to receive
adequate levels of reimbursement from third-party payers, to develop and
maintain a consistent source of commercial supply at a competitive price, and
to obtain and maintain patent protection and regulatory exclusivity. Among the
factors that could cause actual results to differ materially from those
described or projected herein include the following: uncertainties associated
generally with research and development, clinical trials and related
regulatory approvals; the risk that Special Protocol Assessment agreements
with the FDA are not a guarantee that FDA will approve a product candidate
upon submission; the risk that the FDA may not complete its review of the
ANCHOR sNDA by the PDUFA action date or grant new chemical entity regulatory
exclusivity to Vascepa; the risk that historical REDUCE-IT clinical trial
enrollment and randomization rates may not be predictive of future results and
related cost may increase beyond expectations; the risk that patent
applications may not result in issued patents, trade secrets may not be
maintained and that circumstances that create manufacturing barriers to entry
may not last; the risk that Amarin may not enter into a collaboration
agreement for the commercialization of Vascepa in the ANCHOR indication under
favorable terms or at all or market the ANCHOR indication successfully; and
the risk that publications of scientific data may not accept proposals to
publish Vascepa data. A further list and description of these risks,
uncertainties and other risks associated with an investment in Amarin can be
found in Amarin's filings with the U.S. Securities and Exchange Commission,
including its most recent Quarterly Report on Form 10-Q. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.

Vascepa has been approved for use by the FDA as an adjunct to diet to reduce
triglyceride levels in adult patients with severe (≥500 mg/dL)
hypertriglyceridemia. Vascepa is under various stages of development for
potential use in other indications that have not been approved by the FDA.
Nothing in this press release should be construed as marketing the use of
Vascepa in any indication that has not been approved by the FDA.

Important information regarding prescriptions data and product revenue

The historical prescription data provided in this press release is based on
data published by a third party as of May 5, 2013. Although Amarin believes
these data are prepared on a period to period basis in a manner that is
generally consistent and that such results are indicative of current
prescription trends, these data are based on estimates and should not be
relied upon as definitive. These data may overstate or understate actual
prescriptions. Based on other data available to Amarin and the history of such
third-party prescription estimates in the early stages of launch of other new
pharmaceutical products, Amarin believes that while the trends provided by
this information are useful to gauge current prescription levels, such
third-party methods have historically often understated actual prescriptions.
Amarin commenced its commercial launch of Vascepa on January 28, 2013.
Accordingly, there is a very limited amount of information available at this
time to determine the actual number of total prescriptions for Vascepa. Amarin
believes that investors should view these data with caution, as data for this
single and limited period may not be representative of a trend consistent with
the results presented or otherwise predictive of future results. Seasonal
fluctuations in pharmaceutical sales, for example, may affect future
prescription trends of Vascepa as could change in prescriber sentiment and
other factors. Amarin believes investors should consider its results during
this quarter together with its results over several future quarters, or
longer, before making an assessment about potential future performance.

The photo is also available at Newscom, www.newscom.com, and via AP
PhotoExpress.

                                                       
                                                       
CONSOLIDATED BALANCE SHEET DATA
(U.S. GAAP)
Unaudited
                                                       
                                         March 31, 2013 December 31, 2012
                                         (in thousands)
ASSETS                                                                      
Current Assets:                                         
Cash and cash equivalents                 $201,780     $260,242
Restricted cash                           1,400          -----
Accounts receivable                       3,441          -----
Inventory                                27,435         21,262
Deferred tax asset                        937            937
Other current assets                      7,051          3,253
Total Current Assets                      $242,044     $285,694
                                                       
Property, plant and equipment, net        766            811
Deferred tax asset                        11,993         8,044
Other non-current assets                  5,335          4,951
Intangible asset, net                     11,193         11,355
                                                       
Total Assets                              $271,331     $310,855
                                                       
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                              
Current Liabilities:                                   
Accounts payable                          $22,945      $17,458
Accrued interest payable                  4,646          2,520
Deferred revenue                          2,865          -----
Accrued expenses and other liabilities    11,935         5,224
Total current liabilities                 $42,391      $25,202
                                                       
Long Term Liabilities:                                  
Warrant derivative liability              49,011         54,854
Exchangeable senior notes                 137,735        134,250
Long term debt                            85,873         85,153
Long term debt redemption feature         15,600         14,577
Other long term liabilities               807            816
Total liabilities                         $331,417     $314,852
                                                       
Stockholders' Deficit:                                  
Common stock                              124,846        124,597
Additional paid-in capital                625,086        619,266
Treasury stock                            (217)          (217)
Accumulated deficit                       (809,801)      (747,643)
Total stockholders' deficit               $(60,086)    $(3,997)
                                                       
Total Liabilities and Stockholders'       $271,331     $310,855
Deficit

                                                      
                                                      
CONSOLIDATED STATEMENTS OF OPERATIONS DATA
(U.S. GAAP)
Unaudited
                                                      
                                Three Months Ended March 31
                                (in thousands, except share and per share
                                 amounts)
                                2013                   2012
                                                      
Product Revenues                 $2,341               $ -----
                                                      
Operating Expenses:                                    
Cost of goods sold              1,287                  -----
Marketing, general and          39,267                 14,027
administrative(1)
Research and development(1)     21,838                 4,756
Total operating expenses        62,392                 18,783
                                                      
Operating loss                   (60,051)               (18,783)
Gain (loss) on change in fair
value of derivative              3,620                  (66,209)
liabilities(2)
Interest expense, net           (8,860)                (3,951)
Other (expense) income, net     (124)                  68
Loss from operations before      (65,415)               (88,875)
taxes
Benefit for income taxes         3,257                  590
Net and comprehensive loss       $(62,158)            $(88,285)
Loss per share:                                       
Basic and diluted                $(0.41)              $(0.65)
Weighted average shares                                
outstanding:
Basic and diluted                150,430                136,011
                                                      
(1) Amarin's costs include non-cash stock based compensation as well as
warrant based compensation to former officers. Excluding non-cash stock and
warrant based compensation, for 2013 and 2012 marketing, general and
administrative expenses were $35,658 and $8,571 for 2013 and 2012,
respectively, and research and development expenses were $21,024 and $3,964
respectively, for the same periods.
(2) Non-cash charges result from changes in the fair value of the warrant
derivative liability.This liability is revalued at each reporting period and,
upon exercise of warrants, is reclassified at fair value from liability to
stockholders' equity. These warrants are valued using the Black-Scholes option
pricing model, they are classified for accounting purposes as financial
derivatives because, under certain circumstances, the exercise price of the
warrants could increase.

The following is a reconciliation of the non-GAAP financial measures used by
Amarin to describe its financial results determined in accordance with United
States generally accepted accounting principles (GAAP) An explanation of these
measures is also included under the heading "Use of non-GAAP adjusted
financial information" above.

                                                     
RECONCILIATION OF NON-GAAP LIABILITIES
Unaudited
                                                     
                                                     
                                       March 31, 2013 December 31, 2012
                                       (in thousands)
Current Liabilities:                                 
Accounts payable                       $22,945      $17,458
Accrued interest payable               4,646          2,520
Deferred revenue                       2,865          -----
Accrued expenses and other liabilities 11,935         5,224
Total current liabilities              $42,391      $25,202
                                                     
Long-Term Liabilities:                                
Warrant derivative liability           49,011         54,854
Exchangeable senior notes              137,735        134,250
Long-term debt                         85,873         85,153
Long term debt redemption feature     15,600         14,577
Other long-term liabilities            807            816
Total liabilities – GAAP               $331,417     $314,852
Warrant derivative liability           (49,011)       (54,854)
Total liabilities – non GAAP           $282,406     $259,998

                                                               
                                                               
RECONCILIATION OF NON-GAAP NET LOSS
Unaudited
                                                               
                                                 Three Months Ended March 31,
                                                 2013           2012
                                                               
Net loss for EPS^1 – GAAP                        $(62,158)    $(88,285)
Share based compensation expense                 (4,874)        (3,874)
Warrant compensation income (expense)            451            (2,374)
Gain/(loss) on change in fair value of           3,620          (66,209)
derivatives
Adjusted net loss for EPS^1 – non GAAP            $(61,355)    $(15,828)
^1Basic and diluted                                            
Loss per share:                                                 
Basic and diluted – non GAAP                    $(0.41)      $(0.12)
                                                               
Weighted average shares outstanding:                            
Basic and diluted                               150,430        136,011

CONTACT: Amarin Contact Information:
         Joseph Bruno
         Director, Investor Relations and Corporate Communications
         Amarin Corporation plc
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo